恶性肿瘤患者rhGM-CSF治疗前后外周血淋巴细胞亚群的变化
|
摘要
目的探究重组人粒细胞巨噬细胞集落刺激因子(rhGM-CSF)治疗前后肿瘤患者外周血淋巴细胞亚群的变化及临床意义。方法选取2018年3月—2018年10月在我院就诊的30例化疗或放疗后的恶性肿瘤患者作为研究对象。患者放化疗后出现白细胞降低时使用rhGM-CSF治疗,采用流式细胞术检测治疗前后患者外周血中淋巴细胞亚群水平的变化。结果患者治疗后外周血淋巴细胞亚群中CD3~+CD4~+细胞百分率较治疗前明显升高(t=2.826,P<0.05),CD3~+CD8~+细胞百分率明显下降(t=2.932,P<0.05),CD4/CD8比值明显升高(t=3.509,P<0.05)。结论 rhGM-CSF能够增强肿瘤患者机体的免疫应答,提高患者的免疫功能,抑制肿瘤的发生与发展。
Objective To investigate the changes in peripheral blood lymphocyte subsets in patients with malignant tumors after treatment with recombinant human granulocyte macrophage colony-stimulating factor(rhGM-CSF). Methods Thirty patients with malignant tumors treated by chemotherapy or radiotherapy in our hospital from March to October,2018 were selected as study subjects.rhGM-CSF was used to treat patients with decreased leukocyte levels after radiotherapy and chemotherapy.Flow cytometry was used to determine the changes in peripheral blood lymphocyte subsets after treatment. Results After rhGM-CSF treatment,the percentage of CD3~+CD4~+T cells in peripheral blood was significantly increased(t=2.826,P<0.05),the percentage of CD3~+CD8~+T cells was significantly decreased(t=2.932,P<0.05),and the CD4/CD8 ratio was significantly increased(t=3.509,P<0.05). Conclusion rhGM-CSF can strengthen the immune response of tumor patients,improve their immune function,and inhibit the development and progression of tumors.
Objective To investigate the changes in peripheral blood lymphocyte subsets in patients with malignant tumors after treatment with recombinant human granulocyte macrophage colony-stimulating factor(rhGM-CSF). Methods Thirty patients with malignant tumors treated by chemotherapy or radiotherapy in our hospital from March to October,2018 were selected as study subjects.rhGM-CSF was used to treat patients with decreased leukocyte levels after radiotherapy and chemotherapy.Flow cytometry was used to determine the changes in peripheral blood lymphocyte subsets after treatment. Results After rhGM-CSF treatment,the percentage of CD3~+CD4~+T cells in peripheral blood was significantly increased(t=2.826,P<0.05),the percentage of CD3~+CD8~+T cells was significantly decreased(t=2.932,P<0.05),and the CD4/CD8 ratio was significantly increased(t=3.509,P<0.05). Conclusion rhGM-CSF can strengthen the immune response of tumor patients,improve their immune function,and inhibit the development and progression of tumors.
引文
[1]BURGESS A W,CAMAKARIS J,METCALF D.Purification and properties of colony-stimulating factor from mouse lungconditioned medium[J].Journal of Biological Chemistry,1977,252(6):1998-2003.
[2]ZHAO W D,ZHAO G,WANG B.Revisiting GM-CSF as an adjuvant for therapeutic vaccines[J].Cell Mol Immunol,2018,15(2):187-189.
[3]BARROETA SEIJAS A B,SIMONETTI S,VITALE S,et al.GM-CSF inhibits c-kit and SCF expression by bone marrow-derived dendritic cells[J].Front Immunol,2017,8:147.
[4]SCENEAY J,GRIESSINGER C M,HOFFMANN S H L,et al.Tracking the fate of adoptively transferred myeloid-derived suppressor cells in the primary breast tumor microenvironment[J].PLoS One,2018,13(4):e0196040.
[5]APPAY V,VAN LIER R A,SALLUSTO F,et al.Phenotype and function of human T lymphocyte subsets:consensus and issues[J].Cytometry Part A,2008,73A(11):975-983.
[6]周建光,杨梅,曹海涛,等.淋巴细胞亚群的检测在临床的应用[J].东南国防医药,2015,17(3):298-300,321.
[7]姜南雁,唐隽,徐云升.GM-CSF在肿瘤免疫治疗中的作用最新研究进展[J].免疫学杂志,2015,31(8):717-722.
[8]OSTRAND-ROSENBERG S,SINHA P,BEURY D W,et al.Cross-talk between myeloid-derived suppressor cells(MD-SC),macrophages,and dendritic cells enhances tumor-induced immune suppression[J].Semin Cancer Biol,2012,22(4):275-281.
[9]REVOLTELLA R P,MENICAGLI M,CAMPANI D.Granulocyte-macrophage colony-stimulating factor as an autocrine survival-growth factor in human gliomas[J].Cytokine,2012,57(3):347-359.
[10]王海波,刘海义,苏文,等.直肠癌新辅助治疗后外周血调节性T细胞水平与肿瘤缓解的关系[J].中华胃肠外科杂志,2015,18(4):361-364.
[11]LIU Y L,WU Y B,ZHAI K,et al.Determination of interleukin 27-producing CD4(+)and CD8(+)T cells for the differentiation between tuberculous and malignant pleural effusions[J].Sci Rep,2016,6:19424.
[12]慕莹,魏晓芳,王晔,等.恶性肿瘤患者治疗前后外周血淋巴细胞亚群的变化分析[J].生物医学工程与临床,2018,22(2):191-195.
[2]ZHAO W D,ZHAO G,WANG B.Revisiting GM-CSF as an adjuvant for therapeutic vaccines[J].Cell Mol Immunol,2018,15(2):187-189.
[3]BARROETA SEIJAS A B,SIMONETTI S,VITALE S,et al.GM-CSF inhibits c-kit and SCF expression by bone marrow-derived dendritic cells[J].Front Immunol,2017,8:147.
[4]SCENEAY J,GRIESSINGER C M,HOFFMANN S H L,et al.Tracking the fate of adoptively transferred myeloid-derived suppressor cells in the primary breast tumor microenvironment[J].PLoS One,2018,13(4):e0196040.
[5]APPAY V,VAN LIER R A,SALLUSTO F,et al.Phenotype and function of human T lymphocyte subsets:consensus and issues[J].Cytometry Part A,2008,73A(11):975-983.
[6]周建光,杨梅,曹海涛,等.淋巴细胞亚群的检测在临床的应用[J].东南国防医药,2015,17(3):298-300,321.
[7]姜南雁,唐隽,徐云升.GM-CSF在肿瘤免疫治疗中的作用最新研究进展[J].免疫学杂志,2015,31(8):717-722.
[8]OSTRAND-ROSENBERG S,SINHA P,BEURY D W,et al.Cross-talk between myeloid-derived suppressor cells(MD-SC),macrophages,and dendritic cells enhances tumor-induced immune suppression[J].Semin Cancer Biol,2012,22(4):275-281.
[9]REVOLTELLA R P,MENICAGLI M,CAMPANI D.Granulocyte-macrophage colony-stimulating factor as an autocrine survival-growth factor in human gliomas[J].Cytokine,2012,57(3):347-359.
[10]王海波,刘海义,苏文,等.直肠癌新辅助治疗后外周血调节性T细胞水平与肿瘤缓解的关系[J].中华胃肠外科杂志,2015,18(4):361-364.
[11]LIU Y L,WU Y B,ZHAI K,et al.Determination of interleukin 27-producing CD4(+)and CD8(+)T cells for the differentiation between tuberculous and malignant pleural effusions[J].Sci Rep,2016,6:19424.
[12]慕莹,魏晓芳,王晔,等.恶性肿瘤患者治疗前后外周血淋巴细胞亚群的变化分析[J].生物医学工程与临床,2018,22(2):191-195.